Xenetic Biosciences, Inc. - 10-Q Filing
Xenetic Biosciences filed a Form 10-Q for the quarter ended March 31, 2026, reporting royalty revenue of $806,923 and a net loss of $456,382. The company reported operating losses from research and development ($661,443) and general administrative expenses ($647,597). Cash at the end of the quarter was $7.3 million.
Tickers: $XBIO